SCHEMBL209239

SCHEMBL209239

O=Cc1c(Cl)cc(O)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.50
ALDH1A1 P00352 2/20 0.50
CYP3A4 P08684 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
HPGD P15428 1/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
ERN1 O75460 5/20 0.41
TTR P02766 2/20 0.39
BACE1 P56817 2/20 0.38
ALDH5A1 P51649 1/20 0.35
ABAT P80404 1/20 0.35
CHRM1 P11229 1/20 0.35
ALOX15 P16050 1/20 0.35
MAOA P21397 1/20 0.35
TBXA2R P21731 1/20 0.35
ADRA1A P35348 1/20 0.35
HTR2B P41595 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2024626 0.88 ERN1 (0.46) HSD17B10ALDH1A1CYP3A4TDP1HPGD
SCHEMBL16095449 0.84 ERN1 (0.41) HSD17B10ALDH1A1CYP3A4TDP1HPGD
SCHEMBL1459005 0.84 HSD17B10 (0.41) HSD17B10ALDH1A1CYP3A4TDP1HPGD
SCHEMBL4890459 0.78 ESR1 (0.50) ALDH1A1TDP1MEN1KMT2AERN1
SCHEMBL94930 0.78 ALDH1A1 (0.55) HSD17B10ALDH1A1CYP3A4TDP1HPGD
SCHEMBL6111862 0.74 ALDH1A1 (0.50) ALDH1A1TDP1MEN1KMT2AERN1
SCHEMBL17056841 0.74 ALDH1A1 (0.50) ALDH1A1TDP1HPGDMEN1KMT2A
SCHEMBL2429712 0.74 ALDH1A1 (0.50) ALDH1A1TDP1MEN1KMT2AERN1
SCHEMBL320379 0.74 ALDH1A1 (0.50) ALDH1A1TDP1MEN1KMT2AERN1
SCHEMBL3069036 0.73 TTR (0.58) HSD17B10ALDH1A1TDP1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1499577-B1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES HOFFMANN LA ROCHE (CH) 2007-05-30 EP claimed
EP-1499577-A1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-01-26 EP claimed
US-6790852-B2 HETEROCYCLIC NITROGEN COMPOUNDS SUCH AS 2-(2,6-DICHLOROPHENYL) -4-(3-BROMOPHENYL)-5-(2-(3- HYDROXYPROPYLAMINO)PYRIMIDIN-4-YL) -N-H-IMIDAZOLE, USED AS TYROSINE KINASE INHIBITORS; ANTICARCINOGENIC OR ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2004-09-14 US claimed
US-20030199691-A1 2-(2,6-dichlorophenyl)-diarylimidazoles F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 US claimed
WO-2003087026-A1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 WO claimed
US-12528761-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2026-01-20 US disclosed
US-12466781-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2025-11-11 US disclosed
US-20240425437-A1 DERIVATIVES OF SOBETIROME OREGON HEALTH & SCIENCE UNIVERSITY (US) 2024-12-26 US disclosed
CN-115003778-B Boron-containing cyclic light-emitting compound and color conversion film comprising same 日东电工株式会社 2024-09-17 CN disclosed
CN-118251979-A Wavelength conversion film and display device including the same 日东电工株式会社 2024-06-25 CN disclosed
US-12006294-B2 Therapeutic compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2024-06-11 US disclosed
WO-2024081802-A1 WAVELENGTH CONVERSION FILM AND DISPLAY DEVICE INCLUDING THE SAME NITTO DENKO CORPORATION (US) 2024-04-18 WO disclosed
US-20030199691-A1 2-(2,6-dichlorophenyl)-diarylimidazoles F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 US disclosed
WO-2003087026-A1 2-(2,6-DICHLOROPHENYL)-DIARYLIMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-10-23 WO disclosed
US-4853383-A β-blocking substituted imidazoles MERCK & CO., INC. (US) 1989-08-01 US disclosed
US-4642311-A β-adrenergic blocking imidazolylphenoxy propanolamines MERCK & CO., INC. (US) 1987-02-10 US disclosed
US-4567276-A HYPOTENSIVE AGENTS, ADRENERGIC BLOCKING AGENTS MERCK & CO., INC. (US) 1986-01-28 US disclosed
US-4440774-A ANTIHYPERTENSIVE AGENTS AND B-ANDRENERGIC BLOCKING AGENTS MERCK & CO., INC. (US) 1984-04-03 US disclosed
US-4199580-A HYPOTENSIVE AGENTS AND ADRENERGIC BLOCKING AGENTS MERCK & CO., INC. (US) 1980-04-22 US disclosed
US-4134983-A HYPOTENSIVE, ADRENERGIC BLOCKING AGENTS MERCK & CO., INC. (US) 1979-01-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466781-B2 Thyromimetics TPO, TSHR, CHRM1 HSD17B10 1760/4885ALDH1A1 1070/4885CYP3A4 1047/4885
US-12006294-B2 Therapeutic compounds OPRL1, INA, OGFR HSD17B10 4520/4885ALDH1A1 1048/4885CYP3A4 1976/4885
US-20030199691-A1 2-(2,6-dichlorophenyl)-diarylimidazoles CYP2D6, CYP2F1, CYP1A2 HSD17B10 291/4885ALDH1A1 115/4885CYP3A4 49/4885
US-20240425437-A1 DERIVATIVES OF SOBETIROME SNCA, SLC6A3, SLC6A1 HSD17B10 988/4885ALDH1A1 559/4885CYP3A4 788/4885
US-12528761-B2 Thyromimetics TSHR, THRB, TTR HSD17B10 870/4885ALDH1A1 1038/4885CYP3A4 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.